Table 2.
Baseline characteristics of 268 patients with differentiated thyroid cancer included in the study
| Age at diagnosis, years (n = 268) | |
| Mean ± SEM | 45.5 ± 15.7 |
| Median (range) | 45.9 (18–87) |
| Female gender (n = 234) | 87.3% |
| Histology | |
| Papillary classic variant (n = 188) | 70.1% |
| Papillary follicular variant (n = 44) | 16.4% |
| Papillary oncocytic variant (n = 1) | 0.4% |
| Insular variant (n = 1) | 0.4% |
| Poorly differentiated variant (n = 1) | 0.4% |
| Diffuse sclerosing variant (n = 6) | 2.2% |
| Tall cell variant (n = 6) | 2.2% |
| Follicular (n = 15) | 5.6% |
| Hürthle cell (n = 6) | 2.2% |
| T stage | |
| T1a (n = 51) | 19.0% |
| T1b (n = 62) | 23.1% |
| T2 (n = 40) | 14.9% |
| T3 (n = 76) | 28.4% |
| T4 (n = 33) | 12.3% |
| Tx (n = 6) | 2.2% |
| AJCC stage | |
| I (n = 158) | 59.0% |
| II (n = 30) | 11.2% |
| III (n = 33) | 12.3% |
| IV (n = 47) | 17.5% |
| Follow-up duration, months (n = 268) | |
| Mean ± SEM | 92.8 ± 3.3 |
| Median, range | 74.3 (36.1–317.9) |
| 131I cumulative dose, mCi (n = 207) | |
| Mean ± SEM | 367.6 ± 18.7 |
| Median, range | 250 (30–980) |
| Risk of recurrence (modified 2009 RRS) | |
| Low risk (n = 146) | 54.5% |
| Intermediate risk (n = 64) | 23.9% |
| High risk (n = 58) | 21.6% |
SEM, standard error mean; AJCC, American Joint Cancer Committee.